Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Renal Cell × canakinumab × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 3 Primary Myelofibrosis 1 Pancreatic Neoplasms 1 Myelodysplastic Syndromes 1 Metastatic Pancreatic Ductal Adenocarcinoma 1 Leukemia, Myelomonocytic, Chronic 1 Gastrointestinal Neoplasms 1 Clonal Cytopenia of Undetermined Significance 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 66 Sunitinib 63 pembrolizumab 40 cabozantinib 34 Everolimus 33 Sorafenib 32 pazopanib 31 Axitinib 31 Bevacizumab 30 Radiosurgery 29 Ipilimumab 29 Magnetic Resonance Spectroscopy 25 Interleukin-2 23 aldesleukin 21 Specimen Handling 18 Cyclophosphamide 17 lenvatinib 16 fludarabine phosphate 15 Radiotherapy 15 Interferon-alpha 15 temsirolimus 13 Peripheral Blood Stem Cell Transplantation 13 Biopsy 13 Nephrectomy 12 Gemcitabine 12 Blood Specimen Collection 10 durvalumab 9 Immunohistochemistry 9 Capecitabine 9 Mycophenolic Acid 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04028245 2025-08-07

SPARC-1

Columbia University

Phase EARLY_PHASE1 Active not recruiting

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡